Tag Archives: RARE

A Director at Ultragenyx Pharmaceutical is Exercising Options

Yesterday it was reported that a Director at Ultragenyx Pharmaceutical (RARE – Research Report), Clay Siegall, exercised options to sell 34,750 RARE shares at $26.81 a share, for a total transaction value of $2.97M. See today’s analyst top recommended stocks

Ultragenyx Pharmaceutical (RARE) Receives a Hold from Credit Suisse

In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $64.00. The company’s shares closed last Friday at $77.98. According to TipRanks.com, Auster is

J.P. Morgan Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report issued on July 21, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $84.00. The company’s shares closed last Monday at $81.42. According to TipRanks.com,

The SVP, Controller and PAO of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares

Today, the SVP, Controller and PAO of Ultragenyx Pharmaceutical (RARE – Research Report), Theodore Alan Huizenga, sold shares of RARE for $182K. Following Theodore Alan Huizenga’s last RARE Sell transaction on July 06, 2020, the stock climbed by 1.2%. See

The CFO & EVP of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares

Yesterday, the CFO & EVP of Ultragenyx Pharmaceutical (RARE – Research Report), Shalini Sharp, sold shares of RARE for $1.85M. Following Shalini Sharp’s last RARE Sell transaction on September 17, 2019, the stock climbed by 27.4%. This is Sharp’s first

The President & CEO of Ultragenyx Pharmaceutical is Exercising Options

Today it was reported that the President & CEO of Ultragenyx Pharmaceutical (RARE – Research Report), Emil Kakkis, exercised options to buy 149,700 RARE shares at $3.00 a share, for a total transaction value of $449.1K. This recent transaction increases